Cargando…

AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers

Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Bo, Dong, Xu, Wang, Qiujiao, Li, Wei, Zhu, Mingyue, Li, Mengsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061420/
https://www.ncbi.nlm.nih.gov/pubmed/33898423
http://dx.doi.org/10.3389/fcell.2021.635476
_version_ 1783681562771980288
author Lin, Bo
Dong, Xu
Wang, Qiujiao
Li, Wei
Zhu, Mingyue
Li, Mengsen
author_facet Lin, Bo
Dong, Xu
Wang, Qiujiao
Li, Wei
Zhu, Mingyue
Li, Mengsen
author_sort Lin, Bo
collection PubMed
description Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future.
format Online
Article
Text
id pubmed-8061420
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80614202021-04-23 AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers Lin, Bo Dong, Xu Wang, Qiujiao Li, Wei Zhu, Mingyue Li, Mengsen Front Cell Dev Biol Cell and Developmental Biology Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8061420/ /pubmed/33898423 http://dx.doi.org/10.3389/fcell.2021.635476 Text en Copyright © 2021 Lin, Dong, Wang, Li, Zhu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author (s) and the copyright owner (s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Lin, Bo
Dong, Xu
Wang, Qiujiao
Li, Wei
Zhu, Mingyue
Li, Mengsen
AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title_full AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title_fullStr AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title_full_unstemmed AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title_short AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers
title_sort afp-inhibiting fragments for drug delivery: the promise and challenges of targeting therapeutics to cancers
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061420/
https://www.ncbi.nlm.nih.gov/pubmed/33898423
http://dx.doi.org/10.3389/fcell.2021.635476
work_keys_str_mv AT linbo afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers
AT dongxu afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers
AT wangqiujiao afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers
AT liwei afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers
AT zhumingyue afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers
AT limengsen afpinhibitingfragmentsfordrugdeliverythepromiseandchallengesoftargetingtherapeuticstocancers